Poster Schedule

9:45 AM - 1:30 PM PT

(95) Behavioral Addictions Might Be More Common and Harmful Than Previously Thought

9:45 AM - 1:30 PM PT

(96) Mothers in Addiction Treatment: Demographic and Clinical Trends from 2005 to 2025

9:45 AM - 1:30 PM PT

(97) Lift Me Up or Bring Me Down: Partner Influence on Substance Use

9:45 AM - 1:30 PM PT

(98) Substance Use Disorders and Fertility Care: Disparities in Evaluation and Treatment

9:45 AM - 1:30 PM PT

(99) Comparing Postpartum MOUD Monitoring Across Integrated vs Separate Prenatal Care Models

9:45 AM - 1:30 PM PT

(100) EHR Affects Stigma Manifestations and Care Decisions by Peripartum Women With SUD

9:45 AM - 1:30 PM PT

(101) Does Neighborhood Disadvantage Affect Pregnant Patients With Opioid Use Disorder?

9:45 AM - 1:30 PM PT

(102) Start High, Go Fast: Rapid Split-Dose Inpatient Methadone Titration in Pregnancy

9:45 AM - 1:30 PM PT

(103) Treatment Recommendations for Benzodiazepine Use in Pregnancy: A Scoping Review

9:45 AM - 1:30 PM PT

(104) Child Custody Loss and Prenatal Engagement in Pregnant Women With Substance Use

9:45 AM - 1:30 PM PT

(105) Revised Drug Screening Restores Equity Without Compromising Neonatal Safety

9:45 AM - 1:30 PM PT

(106) The Promise of Extended-Release Buprenorphine for Opioid Use Disorder

9:45 AM - 1:30 PM PT

(107) Inadequate Pharmacy Stocking of Buprenorphine in Washington, DC: A Cross-Sectional Survey

9:45 AM - 1:30 PM PT

(108) Associations Between Remission from Opioid Use Disorder and Treatment-Relevant Outcomes

9:45 AM - 1:30 PM PT

(109) Injectable OUD Medications via Telehealth Providers and Local Pharmacies

9:45 AM - 1:30 PM PT

(110) The Effect of Music on Opioid-Related Cue Reactivity

9:45 AM - 1:30 PM PT

(111) GLP-1 Receptor Agonists Improve Outcomes in Patients Receiving Buprenorphine for OUD

9:45 AM - 1:30 PM PT

(112) Buy-In Without a Blueprint: ED Buprenorphine Initiation in Puerto Rico

9:45 AM - 1:30 PM PT

(113) Addiction Medicine Consultation for Patients at Post-Acute Long-Term Care Facilities

9:45 AM - 1:30 PM PT

(114) Early Uptake and Utilization Patterns of Long-Acting Injectable Buprenorphine

9:45 AM - 1:30 PM PT

(115) Higher Buprenorphine Doses Improve Treatment Engagement and Outcomes in Opioid Use Disorder

9:45 AM - 1:30 PM PT

(116) Patient Outcomes After Field-Initiated Buprenorphine With and Without ED Transport

9:45 AM - 1:30 PM PT

(117) Implementing Harm Reduction in a Binational Context: Key Informant Perspectives

9:45 AM - 1:30 PM PT

(118) Opioid-Stimulant Injecting and Smoking: Multilevel Influences in San Diego-Tijuana

9:45 AM - 1:30 PM PT

(119) Closing the Gap: Inpatient Methadone and Telehealth OTP Enrollment

9:45 AM - 1:30 PM PT

(120) Modeling the Effects of Global Opioid Treatment Recommendations on US Methadone and Buprenorphine Access

9:45 AM - 1:30 PM PT

(121) Expanding Access: Empowering Recovery Through Self-Administered Methadone

9:45 AM - 1:30 PM PT

(122) Social Isolation and Loneliness Among Older Adults With Opioid Use Disorder

9:45 AM - 1:30 PM PT

(123) Barriers to Inpatient Use of Opioid-Agonist Therapies

9:45 AM - 1:30 PM PT

(124) Rising Regional Burden of Substance Use Disorders: GBD 2023 Analysis

9:45 AM - 1:30 PM PT

(125) Feasibility of Addiction CaRE: A Program Supporting Hospitalized Patients With SUD

9:45 AM - 1:30 PM PT

(126) Care Barriers & Health Complaints: People Who Inject Drugs in San Antonio

9:45 AM - 1:30 PM PT

(127) Characterizing Quality of Life for People Who Use Drugs

9:45 AM - 1:30 PM PT

(128) Perspectives from People Who Use Drugs: Experiences Using Fentanyl Containing BTMPS

9:45 AM - 1:30 PM PT

(129) Recurrent Overdose Survival Modeling for Smarter Harm Reduction Deployment

9:45 AM - 1:30 PM PT

(130) Recovery Housing Without Abstinence Requirements: Outcomes of a Low-Threshold Pilot

9:45 AM - 1:30 PM PT

(131) Increased Social Support May Provide a Protective Effect Against Recurrent Drug Overdoses

9:45 AM - 1:30 PM PT

(132) Drivers and Deterrents of Accessing Care for Patients With Xylazine-Associated Wounds

9:45 AM - 1:30 PM PT

(133) Rural-Urban Disparities in Tobacco, Alcohol, and Opioid Co-Use Among US Adults, 2021–2023

9:45 AM - 1:30 PM PT

(134) Mapping Non-Fatal Overdoses in Palm Beach County: Spatial Risk Analysis

9:45 AM - 1:30 PM PT

(135) Auditing Documentation Language in OUD Admissions Using Privacy-Preserving Local LLMs

9:45 AM - 1:30 PM PT

(136) Opioid Treatment Engagement and Retention: A Risk and Protective Factor Examination

9:45 AM - 1:30 PM PT

(137) Concurrent Mental Illness in a Fentanyl Cohort: Treatment Gaps and Overdose/Suicide Risks

9:45 AM - 1:30 PM PT

(138) The Impact of Substance Use on Mental Health Care in Adolescents

9:45 AM - 1:30 PM PT

(139) Investigating Mediators Between Antecedent Childhood Trauma and Drug Overdose Among Adults

9:45 AM - 1:30 PM PT

(140) Mapping Psychosocial Pathways From Trauma to Substance Use Risk in Immigrant Adolescents

9:45 AM - 1:30 PM PT

(141) Patient-Provider Relationship Quality in Teens at Risk for Substance Use

9:45 AM - 1:30 PM PT

(142) Naltrexone Treatment for AI Chatbot Addiction in Adolescent With ASD and ADHD

9:45 AM - 1:30 PM PT

(143) Meta-Analysis of Ketamine’s Effects on Craving and Abstinence in Substance Use Disorders

9:45 AM - 1:30 PM PT

(144) Towards Accurate Interpretations of Liver Transplantation Outcomes in Alcohol Use Disorder

9:45 AM - 1:30 PM PT

(145) Alcohol Screening During Surgical Hospitalization Expands Opportunity for Addiction Care

9:45 AM - 1:30 PM PT

(146) Provider-Reported Barriers to Screening and Treating Alcohol Use Disorder

9:45 AM - 1:30 PM PT

(147) Hepatic Failure as an Obstacle in Treating Alcohol Withdrawal and Serotonin Toxicity

9:45 AM - 1:30 PM PT

(148) Tacrolimus Variability With Cannabis Use After Alcohol-Associated Liver Transplant

9:45 AM - 1:30 PM PT

(149) Safety of Naltrexone for Alcohol Use Disorder Treatment in Liver Transplant Recipients

9:45 AM - 1:30 PM PT

(150) Consequences of GLP-1 Coverage Loss in Alcohol Use Disorder

9:45 AM - 1:30 PM PT

(151) Interactions of Gender Identity and Social Factors in Unhealthy Alcohol Use

9:45 AM - 1:30 PM PT

(152) Socioeconomic Status and Unhealthy Alcohol Use Among Transgender Adults

9:45 AM - 1:30 PM PT

(153) Hospital Alcohol Withdrawal Protocol: Improving Outcomes and Reducing Length of Stay

9:45 AM - 1:30 PM PT

(154) When Treatment Turns Toxic: Naltrexone-Induced Psychosis During Alcohol Withdrawal

9:45 AM - 1:30 PM PT

(155) One Measure, Two Stories: How AUDIT vs. AUDIT-C Shape SBIRT Implementation

9:45 AM - 1:30 PM PT

(156) Designing a Contingency Management App to Support Opioid Agonist Therapy

9:45 AM - 1:30 PM PT

(157) Examining National Harm Reduction and Impact on Implementation of Contingency Management

9:45 AM - 1:30 PM PT

(158) Distinct Depression-Craving Trajectories During Naltrexone Treatment for Cocaine Use

9:45 AM - 1:30 PM PT

(159) College Shouldn't be a Relapse Risk: National Evidence on Collegiate Recovery

9:45 AM - 1:30 PM PT

(160) Motivation for Change and Treatment Among Transition-Age Adults With Substance Use Disorder

9:45 AM - 1:30 PM PT

(161) Treating Substance Use Disorder in Interim Housing Settings With Contingency Management

9:45 AM - 1:30 PM PT

(162) Adult Cannabis Usage Pattern in a Rural Ohio Community

9:45 AM - 1:30 PM PT

(163) Naloxone Training Improves Medical Students’ Knowledge and Attitudes: A Two-Year Survey

9:45 AM - 1:30 PM PT

(164) Educational Attainment Levels Shape Substance Use, Disorder Risk, and Care Access

9:45 AM - 1:30 PM PT

(165) Provider Education and Patient Screening for In-Hospital Substance Use: A QI Project

9:45 AM - 1:30 PM PT

(166) Reddit Discussions About Stimulant Use and ADHD Symptoms

9:45 AM - 1:30 PM PT

(167) Creative Arts Groups Promote Connection and Flourishing in SUD Recovery

9:45 AM - 1:30 PM PT

(168) Impact of Resource Linkage on Rehospitalization in People With Substance Use Disorders

9:45 AM - 1:30 PM PT

(169) Live One, Do One, Teach One: Building Recovery Support Services Workforce Capacity

9:45 AM - 1:30 PM PT

(170) From Crisis to Connection: Insights From the THRIVE Peer Recovery Program

9:45 AM - 1:30 PM PT

(171) Bridging Care: Patient Navigation and Support Team Within an Addiction Consult Service

9:45 AM - 1:30 PM PT

(172) Paths to Recovery: An Integrated, Rapid-Access Model for Outpatient Addiction Care

9:45 AM - 1:30 PM PT

(173) Patients With Opioid Use Disorder Report Compassionate Care but Missed Support Opportunity

9:45 AM - 1:30 PM PT

(174) Intensive Community Care Reduces Over-Utilization of Healthcare Resources

9:45 AM - 1:30 PM PT

(175) Provider Perspectives and Understanding of Urine Drug Screening

9:45 AM - 1:30 PM PT

(176) Accuracy of Urine Drug Screen for Substances Other Than Opioids in Pregnancy

9:45 AM - 1:30 PM PT

(177) Predictors of Engagement in a Remote Tobacco Cessation Randomized Trial

9:45 AM - 1:30 PM PT

(178) Predictors of Success in an Intensive, Online Smoking Cessation Program (MINDonline)

9:45 AM - 1:30 PM PT

(179) Outcomes for Patients With Substance Use History Evaluated for Advanced Cardiac Therapies

9:45 AM - 1:30 PM PT

(180) No Colon Left Behind: Increasing Colorectal Cancer Screening Rates Among SUD Patients

9:45 AM - 1:30 PM PT

(181) Inpatient Order Set Increases Initiation of Medications for Substance Use Disorders

9:45 AM - 1:30 PM PT

(182) Evidence for Safety and Tolerability of Transcranial Magnetic Stimulation for SUD

9:45 AM - 1:30 PM PT

(183) Nitrous Oxide Induced Myelopathy With Acute Urinary Retention and Pulmonary Embolism

9:45 AM - 1:30 PM PT

(184) BRAIN GAS: B12 Reduction and Ataxia From Inhaled Nitrous Oxide

9:45 AM - 1:30 PM PT

(185) Trends in Documentation of Stigmatizing Language for Addiction from 2013 to Present

9:45 AM - 1:30 PM PT

(186) Words Do Hurt: Curbing Stigmatizing Words in Substance Use Disorder Treatment